In vivo and in vitro effects of Bletilla striata polysaccharide-loaded paclitaxel nanoparticles on human gastric cancer cells
Purpose: To investigate the in vivo and in vitro effects of paclitaxel nanoparticle (PTX)-loaded Bletilla striata polysaccharide (BSP) on human gastric cancer cells.
Methods: Mice weighing 13 to 17 g and aged 4 to 6 weeks, were inoculated with human gastric gland cancer cell line (MKN45), and randomly assigned to five groups: control group, PTX-1 (10 mk/kg) group; PTX-2 (15 mg/kg) group, BSP-PTX-1 (10 mg/kg) group, and BSP-PTX-2 (15 mg/kg) group. The antiproliferative influence of BSP-PTX and its cellular target were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and fluorescence microscopy, respectively.
Results: Inhibition of MKN45 cells was significantly higher in BSP-PTX group (88.24 %) than in PTX group (76.74 %, p < 0.05). More BSP-PTX entered the cells than PTX. Tumor inhibition was significantly low in PTX-1 group (37.58 %), relative to the BSP-PTX-I group (45.00 %, p < 0.5). In addition, tumor inhibition was significantly lower in PTX-2 group (52.35 %) than in BSP-PTX-2 group (69.80 %, p < 0.5). The weight gain of mice was lower in the PTX or BSP-PTX groups than in control mice, while the weight gain of mice in BSP-PTX-2 group (26.35 %) was significantly higher than that of PTX-2 group (19.43 %, p < 0.5).
Conclusion: Bletilla striata polysaccharide-loaded paclitaxel nanoparticles enhance drug delivery, and effectively and safely exert anti-proliferative effect on MKN45 cells and in mice. Thus, these nanoparticles have good potential for development into anti-gastric cancer agents for clinical application.
Keywords: Bletilla striata polysaccharide, Paclitaxel nanoparticles, Human gastric cancer cells, Tumor target, Liver cancer
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.